Loading clinical trials...

Frovatriptan and Menstrual Migraine | Clinical Trials | Clareo Health

TERMINATED

Frovatriptan and Menstrual Migraine

Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM)

NCT01114711•Mclean Hospital

View on ClinicalTrials.gov

Summary

We are looking for women who suffer from menstrual migraine to participate in a 2-visit migraine brain imaging research study. Our goal is to see how the menstrual migraine brain's pain pathways function when the migraineur has been taking Frovatriptan. During the screening visit (Visit 1) participants will sign the informed consent form, complete questionnaires, meet with the study physician, and have QST (quantitative sensory testing: to determine your pain thresholds for a heat stimulus) performed. For Visit 2's MRI scan, subjects will be asked to lie very still while the scan is occurring. In some parts, they will not have to do anything, while in others they will be asked to rate pain and unpleasantness for brush and thermal stimuli. Participants are compensated for both visits.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Female
•Regular Menstrual Phase
•Menstrual Migraine
•No significant medical history (Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc.)
•No significant medication history, except for migraine
•All patients will be currently taking or have previously taken triptan medications for migraine
•Weight, \<285 pounds
•Not claustrophobic
•No contraindication to taking triptans

Exclusion Criteria

•Age \<18
•Significant medical problems (aside from pain before, during and after migraine episodes)
•Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.)
•Positive alcohol screen
•Women taking oral contraceptives
•Claustrophobia
•History of dermatological hypersensitivity in the facial area
•Positive history of cardiac problems/ abnormalities seen in EKG at initial screening visit
•Pregnancy
•Sensory loss detected on Quantitative Sensory Testing at screening
+23 more criteria

Locations (1)

Neuroimaging Center, McLean Hospital

Belmont, Massachusetts, United States

Key Dates

Start Date

April 1, 2010

Primary Completion Date

May 1, 2010

Completion Date

May 1, 2010

Last Updated

April 12, 2018

Enrollment

ACTUAL participants

Conditions

FrovatriptanMenstrual Migraine

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466

Menstrual Migraine

View study

COMPLETED

Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine

NCT04600388

Menstrual Migraine

View study

UNKNOWN

Detecting Auricular Points in MMG by a Novel APD ( APD-MMG )

NCT03702114

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions